- 53 LR:
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPintherapeutics, today announced its interim management statement for the quarter ending September 30, 2021.
- COVID-19 continues to be a major concern globally, and a main focus of our efforts at Molecular Partners.
- Having now enrolled over 700 patients across two global late stage studies, we have accomplished much and are approaching two significant milestones.
- Molecular Partners collaboration partner, Novartis, is conducting the clinical trial for ensovibep, with Molecular Partners as a sponsor.